Larimar Therapeutics, Inc.
nomlabofusp
Friedreich's ataxia (FA)
Date
TBD
FDA decision · Date TBD estimated
What's at stake
An FDA complete response letter on nomlabofusp for Friedreich's ataxia (FA) is in focus around Date TBD.
Primary source
· SEC 8-K
verified 13h ago
“The adequacy of the safety dataset will be a matter of review at the time of BLA submission.”